This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.

Perspectives on managing CML video

Speakers: Andrea Preston/Rebecca Hallam

Duration: 3:40

In this video, Rebecca and Andrea discuss how in their roles of Nurse Specialist and Pharmacist, they support patients during their initial diagnosis of Chronic Myeloid Leukaemia (CML) and during their treatment.  Topics mentioned are adherence, choosing the right TKI (Tyrosine Kinase Inhibitor), side effects and individualised treatment for patients.

Andrea Preston is the Divisional Lead Pharmacist for Haematology and Oncology at University Hospital Bristol NHS Foundation Trust.  She is also a Cancer Commissioning Pharmacist, providing expert oncology and haematology pharmacy advice to the Specialised Commissioing Team of NHS England, in the South West. Andrea is a subcommitee member of the British Oncology Pharmacy Association Audit and Research Committee and has a special interest in dosing of systemic anticancer therapy in obesity.   This interest started during her MSc in Clinical Oncology and her research has been presented at conferences including the British Oncology Pharmacy Association Conference, European Haematology Association conferecnes and the International Conference for Malignant Lymphoma.

Rebecca Hallam is the BMT Advanced Clinical Practitioner also based at the University Hospital Bristol NHS Foundation Trust. During her career, Rebecca has established a nurse-led myeloproliferative disorder clinic, a nurse-led chemotherapy pre-assessment clinic and an e-journal club for nurses on the chemotherapy day unit; she has also implemented the frailty identification tool within haemato-oncology clinics. Rebecca's special interests are in long-term follow-up, late effects of cancer treatment and fraility in haemato-oncology. She holds the position of Secretary of the Haematology Members' Interest Group of UK Oncology Nursing Society.

Explore more

Review ELN Guidelines

Compare 2013 guidelines to those published in 2020

Explore More

New challenges: long-term TKI therapy

Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video

Watch the video

 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
PP-BOS-GBR-1308. September 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020